Fennec Pharmaceuticals (FENC) Expects 'PEDMARK' Expansion... 73% Revenue Surge and Turn to Profit
Fennec Pharmaceuticals (FENC) is rapidly expanding its market influence with 'PEDMARK' due to expanded clinical evidence and commercial success, reporting a 73% revenue surge and a turn to profitability.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 51.8%.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel